PIMOBENDAN VETMEDICA 2,5 MG COMPRIME A CROQUER POUR CHIENS
국가: 프랑스
언어: 영어
출처: HMA (Heads of Medicines Agencies)
환자 정보 전단 유효 성분:
pimobendan 2.5 mg
제공처:
Boehringer Ingelheim Vetmedica GmbH
ATC 코드:
QC01CE90
약제 형태:
Chewable tablet
치료 그룹:
pimobendane
치료 영역:
Dogs
승인 날짜:
2012-01-27
환자 정보 전단
1
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Vetmedin 2.5 mg chewable tablets for dogs
(AT, BG, CY, CZ, EE, EL, HU, LV, LT, PL, RO, SI, SK, ES, IS, LI, PT, BE, LU, NL)
[Pimobendan Vetmedica 2.5 mg chewable tablets for dogs
(FI, FR, IE, IT, SE, UK)
Pimobendan Boehringer Ingelheim Vetmedica GmbH 2.5 mg chewable tablets for dogs
(NO)
The name ‘the product’ will be used in the product information]
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One chewable tablet contains:
ACTIVE SUBSTANCE:
Pimobendan
2.5 mg
EXCIPIENTS:
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Chewable tablet
Oblong, scored, mottled brown tablets with fine white spots, embossed with Boehringer Ingelheim
logo and P02.
The tablet can be divided into equal halves.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dog
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or
valvular insufficiency (mitral and/or tricuspid valve regurgitation).
(See also section 4.9).
4.3
CONTRAINDICATIONS
[The product] is not to be used in hypertrophic cardiomyopathies or in diseases in which an
improvement in cardiac output cannot be achieved for functional or anatomical reasons (e.g. aortic
stenosis).
Since [the product] is metabolised mainly via the liver, it should not be used in dogs with severe
impairment of liver function (see also 4.7).
3
4.4
SPECIAL WARNINGS
None.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS F
전체 문서 읽기
제품 특성 요약
1
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Vetmedin 2.5 mg chewable tablets for dogs
(AT, BG, CY, CZ, EE, EL, HU, LV, LT, PL, RO, SI, SK, ES, IS, LI, PT, BE, LU, NL)
[Pimobendan Vetmedica 2.5 mg chewable tablets for dogs
(FI, FR, IE, IT, SE, UK)
Pimobendan Boehringer Ingelheim Vetmedica GmbH 2.5 mg chewable tablets for dogs
(NO)
The name ‘the product’ will be used in the product information]
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One chewable tablet contains:
ACTIVE SUBSTANCE:
Pimobendan
2.5 mg
EXCIPIENTS:
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Chewable tablet
Oblong, scored, mottled brown tablets with fine white spots, embossed with Boehringer Ingelheim
logo and P02.
The tablet can be divided into equal halves.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dog
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or
valvular insufficiency (mitral and/or tricuspid valve regurgitation).
(See also section 4.9).
4.3
CONTRAINDICATIONS
[The product] is not to be used in hypertrophic cardiomyopathies or in diseases in which an
improvement in cardiac output cannot be achieved for functional or anatomical reasons (e.g. aortic
stenosis).
Since [the product] is metabolised mainly via the liver, it should not be used in dogs with severe
impairment of liver function (see also 4.7).
3
4.4
SPECIAL WARNINGS
None.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS F
전체 문서 읽기
